A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)

Trial Profile

A Phase I Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 25 Jun 2014

At a glance

  • Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors Merck & Co
  • Most Recent Events

    • 21 Mar 2013 Actual end date (March 2007) added as reported by ClinicalTrials.gov.
    • 04 May 2010 Merck Sharp and Dohme added as trial affiliate as reported by ClinicalTrials.gov.
    • 16 Jun 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top